Evidence map›Paper›PMID 37631893›Full record

ArticleVaccines2023

COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up.

Annalisa Rosso, Maria Elena Flacco, Graziella Soldato, Giuseppe Di Martino, Cecilia Acuti Martellucci, Roberto Carota, Marco De Benedictis, Graziano Di Marco, Rossano Di Luzio, Matteo Fiore and 2 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Annalisa RossoDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-0537-5130
Maria Elena FlaccoDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.
Graziella SoldatoLocal Health Unit of Pescara, 65124 Pescara, Italy.
Giuseppe Di MartinoLocal Health Unit of Pescara, 65124 Pescara, Italy.ORCID 0000-0001-7047-7611
Cecilia Acuti MartellucciDepartment of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0002-4308-2144
Roberto CarotaLocal Health Unit of Pescara, 65124 Pescara, Italy.
Marco De BenedictisLocal Health Unit of Pescara, 65124 Pescara, Italy.
Graziano Di MarcoLocal Health Unit of Pescara, 65124 Pescara, Italy.
Rossano Di LuzioLocal Health Unit of Pescara, 65124 Pescara, Italy.
Matteo FioreDepartment of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy.ORCID 0000-0001-6868-2130
Antonio CaponettiLocal Health Unit of Pescara, 65124 Pescara, Italy.
Lamberto ManzoliDepartment of Medical and Surgical Sciences, University of Bologna, 40100 Bologna, Italy.ORCID 0000-0002-8129-9344
Azienda USL di Pescara · ITUniversity of Ferrara · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We carried out a cohort study on the overall population of the province of Pescara, Italy, to assess the real-world effectiveness of SARS-CoV-2 vaccination against infection, severe, or lethal COVID-19, two years after the start of the vaccination campaign. We included all the resident or domiciled subjects, and extracted the official demographic, vaccination, COVID-19, hospital and co-pay exemption datasets from 1 January 2021, up to 15 February 2023. Cox proportional hazards analyses were adjusted for gender, age, diabetes, hypertension, COPD, major cardio- and cerebrovascular events, cancer, and kidney diseases. Throughout the follow-up (466 days on average), 186,676 subjects received greater than or equal to three vaccine doses (of ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, NVX-CoV2373, or JNJ-78436735), 47,610 two doses, 11,452 one dose, and 44,989 none. Overall, 40.4% of subjects were infected with SARS-CoV-2. Of them, 2.74% had severe or lethal (1.30%) COVID-19. As compared to the unvaccinated, the individuals who received greater than or equal to one booster dose showed a ≥85% lower risk of severe or lethal COVID-19. A massive impact of vaccination was found among the elderly: 22.0% of the unvaccinated, infected individuals died, as opposed to less than 3% of those who received greater than or equal to three vaccine doses. No protection against infection was observed, although this finding was certainly influenced by the Italian restriction policies to control the pandemic. Importantly, during the Omicron predominance period, only the group who received at least a booster dose showed a reduced risk of COVID-19-related death.

Indexed as

cohort studyCOVID-19ItalySARS-CoV-2vaccine

Identifiers

PMID37631893
PMCPMC10459219
OpenAlexW4385602884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.